Nurix Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation (TPD) medicines. Leveraging its proprietary DEL-AI platform and deep expertise in E3 ligases, the company designs small molecules that either harness or inhibit the ubiquitin-proteasome system to selectively modulate cellular protein levels. Nurix's clinical-stage pipeline is anchored by bexobrutideg (NX-5948), an oral, CNS-penetrant Bruton's tyrosine kinase (BTK) degrader being evaluated for B-cell malignancies and autoimmune diseases, alongside other candidates like zelebrudomide (NX-2127) and NX-1607.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Implementing a comprehensive global clinical development and registrational program for lead BTK degrader bexobrutideg, including the pivotal Phase 2 DAYBreak CLL-201 study and the confirmatory Phase 3 DAYBreak CLL-306 study.
Expected impact: Aims to establish bexobrutideg as a best-in-class therapeutic option for relapsed/refractory CLL and support accelerated and full global regulatory approvals.
Expanding the clinical utility of bexobrutideg into autoimmune and inflammatory indications, supported by healthy volunteer studies evaluating a new oral tablet formulation.
Expected impact: Enables entry into high-value autoimmune markets where targeted protein degradation of BTK offers advantages over traditional BTK inhibitors.
Utilizing the proprietary DNA-encoded library (DEL) platform integrated with artificial intelligence (DEL-AI) to discover and advance novel E3 ligase-based protein degraders.
Expected impact: Sustains a highly productive discovery pipeline to fuel both wholly owned programs and partnered portfolios.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Combines Nurix's targeted protein degradation expertise with Roche's global clinical and commercial infrastructure to maximize the potential of lead asset bexobrutideg across oncology, immunology, and neurology.
Terms: Nurix receives a $700 million upfront cash payment and is eligible for up to $2.3 billion in total potential development, regulatory, and sales milestones. Development costs are shared 40% by Nurix and 60% by Roche. U.S. profits and losses are split 50/50, and Nurix is eligible for tiered royalties from the low- to high-teens on ex-U.S. sales.
Collaborating to discover and develop targeted protein degraders, including an IRAK4 degrader program which Gilead has advanced into Phase 1 clinical testing.
Terms: Extended in 2024 for an additional two years with a $15 million extension fee paid to Nurix. Nurix retains options for co-development and 50/50 U.S. profit sharing on selected programs.
Collaborating on the discovery and development of targeted protein degraders, including a STAT6 degrader program (NX-3911) for autoimmune and inflammatory diseases.
Terms: Extended in April 2025 with a $15 million extension fee, bringing total upfront and extension payments to $105 million, with potential for up to $465 million in future milestones per program plus royalties.
Leveraging Nurix's DEL-AI platform to discover and develop targeted protein degraders for multiple targets.
Terms: Nurix is eligible to receive research milestones and potential licensing fees throughout the term of the collaboration.